On June 16, 2020 Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported a poster presentation of the results for preclinical studies evaluating the administration of ROLONTIS on the same day as chemotherapy in a rodent model (Press release, Spectrum Pharmaceuticals, JUN 16, 2020, View Source [SID1234561126]). The abstract titled "Chemotherapy induced neutropenia in rats following administration of eflapegrastim or pegfilgrastim on the same day at three different timepoints and at 24 hours post-chemotherapy" will be part of the Special Populations, Survivorship, Outcomes, and Supportive Care session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, to be held June 22-24, 2020. Full details of the poster are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstract Title: Chemotherapy induced neutropenia in rats following administration of eflapegrastim or pegfilgrastim on the same day at three different timepoints and at 24 hours post-chemotherapy
Authors: Yu-Yon Kim., et al.
Session: Special Populations, Survivorship, Outcomes, and Supportive Care
Date and Time: June 22, 2020, 9 a.m. – 6 p.m. EDT
Poster Number: 2044 / 22
Location: Access to the AACR (Free AACR Whitepaper) Virtual Annual Meeting II will be free to everyone. While access will be free, attendees will be required to register to view the meeting. Registration for the meeting is available through the myAACR portal.